Microbial polysaccharide: New insights for treating autoimmune diseases

Frontiers in Bioscience - Scholar

Volumn 2 S, Issue 1, 2010, Pages 256-267

  Vecchiarelli, Anna ^a   Monari, Claudia ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Apoptosis; Glucuronoxylomannan; GXM; Immunosuppressive effects; Monocytes Macrophages; Review; Rheumatoid Arthritis; Septic arthritis

Indexed keywords

ANTIINFLAMMATORY AGENT; GLUCURONOXYLOMANNAN; IMMUNOSUPPRESSIVE AGENT; POLYSACCHARIDE;

AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CHEMISTRY; CRYPTOCOCCUS NEOFORMANS; DRUG EFFECT; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; REVIEW; T LYMPHOCYTE;

ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; CRYPTOCOCCUS NEOFORMANS; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; POLYSACCHARIDES; T-LYMPHOCYTES;

EID: 77957310910     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s62     Document Type: Article

References (101)

1. MA Gates, P Thorkildson, TR Kozel: Molecular architecture of the Cryptococcus neoformans capsule. Mol Microbiol 52, 13-24 (2004) (Pubitemid 38519618)
2. A Casadevall, J R Perfect. Cryptococcus neoformans. American Society for Mcrobiology Press, Washington DC (1998)
3. R Cherniak, JB Sundstrom: Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect Immun 62, 1507-1512 (1994) (Pubitemid 24136940)
4. VV Vaishnav, BE Bacon, M O'Neill, R Cherniak: Structural characterization of the galactoxylomannan of Cryptococcus neoformans Cap67. Carbohydr Res 306, 315-330 (1998) (Pubitemid 28305000)
5. D McFadden, O Zaragoza, A Casadevall: The capsular dynamics of Cryptococcus neoformans. Trends Microbiol 14, 497-505 (2006) (Pubitemid 44559749)
6. DC McFadden,M De Jesus,A Casadevall: The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction. J Biol Chem 281, 1868-1875 (2006) (Pubitemid 43845771)
7. E Reiss,R Cherniak,R Eby,L Kaufman: Enzyme immunoassay detection of IgM to galactoxylomannan of Cryptococcus neoformans. Diagn Immunol, 2, 109-115 (1984) (Pubitemid 15189763)
8. PG James, R Cherniak: Galactoxylomannans of Cryptococcus neoformans. Infect Immun 60, 1084-1088 (1992)
9. R Cherniak, H Valafar, LC Morris, F Valafar: Cryptococcus neoformans chemotyping by quantitative analysis of 1H nuclear magnetic resonance spectra of glucuronoxylomannans with a computer-simulated artificial neural network. Clin Diagn Lab Immunol 5, 146-159 (1998) (Pubitemid 28161182)
10. A Nakouzi, T Zhang, S Oscarson, A Casadevall: The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies. Vaccine 27, 3513-3518 (2009)
11. M Feldmesser, Y Kress, A Casadevall: Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology 147, 2355-2365 (2001) (Pubitemid 32785515)
12. J Garcia-Rivera, YC Chang, KJ Kwon-Chung, A Casadevall: Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan. Eukaryot Cell 3, 385-392 (2004) (Pubitemid 38497977)
13. A Yoneda, TL Doering: A eukaryotic capsular polysaccharide is synthesized intracellularly and secreted via exocytosis. Mol Biol Cell 17, 5131-5140 (2006) (Pubitemid 44907356)
14. ML Rodrigues, L Nimrichter, DL Oliveira, S Frases, K Miranda, O Zaragoza, M Alvarez, A Nakouzi, M Feldmesser, A Casadevall: Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport. Eukaryot Cell 6, 48-59 (2007) (Pubitemid 46147652)
15. O Zaragoza, A Telzak, RA Bryan, E Dadachova, A Casadevall: The polysaccharide capsule of the pathogenic fungus Cryptococcus neoformans enlarges by distal growth and is rearranged during budding. Mol Microbiol 59, 67-83 (2006)
16. S Frases, L Nimrichter, NB Viana, A Nakouzi, A Casadevall: Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. Eukaryot Cell 7, 319-327 (2008) (Pubitemid 351959699)
17. R Cherniak, E Reiss, ME Slodki, RD Plattner, SO Blumer: Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A. Mol Immunol 17, 1025-1032 (1980) (Pubitemid 10087383)
18. DC Houpt, GS Pfrommer, BJ Young, TA Larson, TR Kozel: Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect Immun 62, 2857-2864 (1994) (Pubitemid 24203971)
19. M Grinsell, LC Weinhold, JE Cutler, Y Han, TR Kozel: In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages. J Infect Dis 184, 479-487 (2001) (Pubitemid 32718512)
20. LE Yauch, MK Mansour, SM Levitz: Receptor-mediated clearance of Cryptococcus neoformans capsular polysaccharide in vivo. Infect Immun 73, 8429-8432 (2005) (Pubitemid 41740337)
21. RH Eng, E Bishburg, SM Smith, R Kapila: Cryptococcal infections in patients with acquired immune deficiency syndrome. Am J Med 81, 19-23 (1986) (Pubitemid 16044505)
22. W Chaka, AF Verheul, VV Vaishnav, R Cherniak, J Scharringa, J Verhoef, H Snippe, IM Hoepelman: Cryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan, and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cells. Infect Immun 65, 272-278 (1997) (Pubitemid 27008933)
23. E Pericolini, E Cenci, C Monari, M De Jesus, F Bistoni, A Casadevall, A Vecchiarelli: Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8. Cell Microbiol 8, 267-275 (2006) (Pubitemid 43356049)
24. C Monari, TR Kozel, A Casadevall, D Pietrella, B Palazzetti, A Vecchiarelli: B7 costimulatory ligand regulates development of the T-cell response to Cryptococcus neoformans. Immunology 98, 27-35 (1999) (Pubitemid 29425905)
25. D Pietrella, C Monari, C Retini, B Palazzetti, TR Kozel, A Vecchiarelli: HIV type 1 envelope glycoprotein gp120 induces development of a T helper type 2 response to Cryptococcus neoformans. AIDS 13, 2197-2207 (1999) (Pubitemid 29531439)
26. A Vecchiarelli, D Pietrella, P Lupo, F Bistoni, DC McFadden, A Casadevall: The polysaccharide capsule of Cryptococcus neoformans interferes with human dendritic cell maturation and activation. J Leukoc Biol 74, 370-378 (2003) (Pubitemid 38040397)
27. RM Syme, TF Bruno, TR Kozel, CH Mody: The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody. Infect Immun 67, 4620-4627 (1999) (Pubitemid 29400441)
28. C Retini, A Vecchiarelli, C Monari, F Bistoni, TR Kozel: Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes. Infect Immun 66, 664-669 (1998) (Pubitemid 28074210)
29. C Retini, A Casadevall, D Pietrella, C Monari, B Palazzetti, A Vecchiarelli: Specific activated T cells regulate IL-12 production by human monocytes stimulated with Cryptococcus neoformans. J Immunol 162, 1618-23 (1999) (Pubitemid 29307037)
30. C Monari, E Pericolini, G Bistoni, A Casadevall, TR Kozel, A Vecchiarelli: Cryptococcus neoformans capsular glucuronoxylomannan induces expression of fas ligand in macrophages. J Immunol 174, 3461-3468 (2005) (Pubitemid 40354053)
31. SN Villena, RO Pinheiro, CS Pinheiro, MP Nunes, CM Takiya, GA DosReis, JO Previato, L Mendonca-Previato, CG Freire-de-Lima: Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand. Cell Microbiol 10, 1274-1285 (2008) (Pubitemid 351663919)
32. A Vecchiarelli, C Retini, D Pietrella, C Monari, C Tascini, T Beccari, TR Kozel: Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes. Infect Immun 63, 2919-2923 (1995)
33. A Vecchiarelli, C Retini, C Monari, C Tascini, F Bistoni, TR Kozel: Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun 64, 2846-9 (1996) (Pubitemid 26226860)
34. C Retini, TR Kozel, D Pietrella, C Monari, F Bistoni, A Vecchiarelli: Interdependency of interleukin-10 and interleukin-12 in regulation of T-cell differentiation and effector function of monocytes in response to stimulation with Cryptococcus neoformans. Infect Immun, 69, 6064-6073 (2001) (Pubitemid 32885166)
35. G Nussbaum, W Cleare, A Casadevall, MD Scharff, P Valadon: Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J Exp Med 185, 685-694 (1997) (Pubitemid 27098153)
36. TC MacGill, RS MacGill, A Casadevall, TR Kozel: Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans. J Immunol, 164, 4835-4842 (2000) (Pubitemid 30238087)
37. T Belay, R Cherniak: Determination of antigen binding specificities of Cryptococcus neoformans factor sera by enzyme-linked immunosorbent assay. Infect Immun, 63, 1810-1819 (1995)
38. Kozel, T R, S M Levitz, F Dromer, M A Gates, P Thorkildson and G Janbon: Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains. Infect Immun, 71, 2868-75 (2003) (Pubitemid 36519900)
39. TF Eckert, TR Kozel: Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide. Infect Immun, 55, 1895-1899 (1987)
40. PM Ellerbroek, DJ Lefeber, R van Veghel, J Scharringa, E Brouwer, GJ Gerwig, G Janbon, AI Hoepelman, FE Coenjaerts: O-acetylation of cryptococcal capsular glucuronoxylomannan is essential for interference with neutrophil migration. J Immunol 173, 7513-7520 (2004) (Pubitemid 39628192)
41. RG Washburn, BJ Bryant-Varela, NC Julian, JE Bennett: Differences in Cryptococcus neoformans capsular polysaccharide structure influence assembly of alternative complement pathway C3 convertase on fungal surfaces. Mol Immunol 28, 465-470 (1991)
42. TR Kozel, EC Gotschlich: The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J Immunol 129, 1675-1680 (1982) (Pubitemid 12031112)
43. YY Tian, Y Liu, XF Zhao, JX Wang: Characterization of a C-type lectin from the cotton bollworm, Helicoverpa armigera. Dev Comp Immunol 33, 772-779 (2009)
44. ZM Dong, JW Murphy: Cryptococcal polysaccharides bind to CD18 on human neutrophils. Infect Immun 65, 557-563 (1997) (Pubitemid 27053225)
45. C Monari, C Retini, A Casadevall, D Netski, F Bistoni, TR Kozel, A Vecchiarelli: Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils. Eur J Immunol, 33, 1041-1051 (2003) (Pubitemid 36546692)
46. ZL Chang, D Netski, P Thorkildson, TR Kozel: Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages. Infect Immun 74, 144-151 (2006) (Pubitemid 43023068)
47. C Monari, F Bistoni, A Casadevall, E Pericolini, D Pietrella, TR Kozel A Vecchiarelli: Glucuronoxylomannan, a microbial compound, regulates expression of costimulatory molecules and production of cytokines in macrophages. J Infect Dis 191, 127-137 (2005) (Pubitemid 40041411)
48. S Shoham, C Huang, JM Chen, DT Golenbock, SM Levitz: Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol 166, 4620-4626 (2001) (Pubitemid 32233748)
49. RJ Carmody, YH Chen: Nuclear factor-kappaB: activation and regulation during toll-like receptor signaling. Cell Mol Immunol 4, 31-41 (2007)
50. A Bowie, LA O'Neill: The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J Leukoc Biol 67, 508-514 (2000)
51. C Monari, TR Kozel, F Paganelli, E Pericolini, S Perito, F Bistoni, A Casadevall, A Vecchiarelli: Microbial immune suppression mediated by direct engagement of inhibitory Fc receptor. J Immunol 177, 6842-6851 (2006) (Pubitemid 44715049)
52. IE Van den Herik-Oudijk, PJ Capel, T van der Bruggen, JG Van de Winkel: Identification of signaling motifs within human Fc gamma RIIa and Fc gamma RIIb isoforms. Blood 85, 2202-2211 (1995)
53. T Takai: Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2, 580-592 (2002) (Pubitemid 37328733)
54. JV Ravetch, LL Lanier: Immune inhibitory receptors. Science 290, 84-89 (2000)
55. M Daeron: Fc receptor biology. Annu Rev Immunol 15, 203-234 (1997) (Pubitemid 27169280)
56. P Bruhns, F Vely, O Malbec, WH Fridman, E Vivier, M Daeron: Molecular basis of the recruitment of the SH2 domain-containing inositol 5-phosphatases SHIP1 and SHIP2 by fcgamma RIIB. J Biol Chem 275, 37357-3764 (2000)
57. NE Phillips, DC Parker: Fc-dependent inhibition of mouse B cell activation by whole anti-mu antibodies. J Immunol 130, 602-606 (1983) (Pubitemid 13186273)
58. S Latour, WH Fridman, M Daeron: Identification, molecular cloning, biologic properties, and tissue distribution of a novel isoform of murine low-affinity IgG receptor homologous to human Fc gamma RIIB1. J Immunol 157, 189-197 (1996) (Pubitemid 26190547)
59. C Monari, F Bistoni, A Vecchiarelli: Glucuronoxylomannan exhibits potent immunosuppressive properties. FEMS Yeast Res 6, 537-542 (2006) (Pubitemid 43725737)
60. DR Green: Overview: apoptotic signaling pathways in the immune system. Immunol Rev 193, 5-9 (2003) (Pubitemid 36688034)
61. PH Krammer: CD95's deadly mission in the immune system. Nature 407, 789-795 (2000)
62. LS Chiapello, JL Baronetti, AP Garro, MF Spesso, DT Masih: Cryptococcus neoformans glucuronoxylomannan induces macrophage apoptosis mediated by nitric oxide in a caspase-independent pathway. Int Immunol 20, 1527-1541 (2008)
63. C Monari, F Paganelli, F Bistoni, TR Kozel, A Vecchiarelli: Capsular polysaccharide induction of apoptosis by intrinsic and extrinsic mechanisms. Cell Microbiol 10, 2129-2137 (2008)
64. EM Creagh, H Conroy, SJ Martin: Caspase-activation pathways in apoptosis and immunity. Immunol Rev 193, 10-21 (2003) (Pubitemid 36688035)
65. H Pollard, S Granger, PJ Tuchin: Bacterial arthritis A review. Australas Chiropr Osteopathy 8, 45-53 (1999)
66. CJ Baker, MS Edwards: Group B streptococcal infections Perinatal impact and prevention methods. Ann N Y Acad Sci 549, 193-202 (1988)
67. MS Edwards, CJ Baker: Group B streptococcal infections in elderly adults. Clin Infect Dis, 41, 839-847 (2005) (Pubitemid 41266752)
68. A Schattner, K Vosti: Recurrent group B streptococcal arthritis. Clin Rheumatol 17, 387-389 (1998) (Pubitemid 28483137)
69. L Tissi, M Puliti, R Barluzzi, G Orefici, C von Hunolstein, F Bistoni: Role of tumor necrosis factor alpha, interleukin-1beta, and interleukin-6 in a mouse model of group B streptococcal arthritis. Infect Immun 67, 4545-4550 (1999) (Pubitemid 29400431)
70. L Tissi, P Marconi, P Mosci, L Merletti, P Cornacchione, E Rosati, S Recchia, C von Hunolstein, G Orefici: Experimental model of type IV Streptococcus agalactiae (group B streptococcus) infection in mice with early development of septic arthritis. Infect Immun 58, 3093-3100 (1990) (Pubitemid 20267708)
71. FA van de Loo, LA Joosten, PL van Lent, OJ Arntz, WB van den Berg: Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 38, 164-172 (1995)
72. WP Arend, JM Dayer: Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33, 305-315 (1990) (Pubitemid 20109181)
73. A Ito, Y Itoh, Y Sasaguri, M Morimatsu,Y Mori: Effects of interleukin-6 on the metabolism of connective tissue components in rheumatoid synovial fibroblasts. Arthritis Rheum 35, 1197-1201 (1992)
74. JJ Nietfeld, B Wilbrink, M Helle, JL van Roy, W den Otter, AJ Swaak, O Huber-Bruning: Interleukin-1-induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. Arthritis Rheum 33, 1695-1701 (1990)
75. J Green, S Schotland, Z Sella, CR Kleeman: Interleukin-6 attenuates agonist-mediated calcium mobilization in murine osteoblastic cells. J Clin Invest 93, 2340-2350 (1994) (Pubitemid 24177144)
76. L Tissi, M Puliti, F Bistoni, P Mosci, TR Kozel, A Vecchiarelli: Glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, inhibits the progression of group B streptococcal arthritis. Infect Immun 72, 6367-6372 (2004) (Pubitemid 39425417)
77. ZM Dong, JW Murphy: Intravascular cryptococcal culture filtrate (CneF) and its major component, glucuronoxylomannan, are potent inhibitors of leukocyte accumulation. Infect Immun 63, 770-778 (1995)
78. C Monari, TR Kozel, F Bistoni, A Vecchiarelli: Modulation of C5aR expression on human neutrophils by encapsulated and acapsular Cryptococcus neoformans. Infect Immun 70, 3363-3370 (2002) (Pubitemid 34665971)
79. JJ Goronzy, CM Weyand: Rheumatoid arthritis. Immunol Rev 204, 55-73 (2005) (Pubitemid 40460493)
80. IB McInnes, G Schett: Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7, 429-442 (2007) (Pubitemid 46834849)
81. YG Cho, ML Cho, SY Min, HY Kim: Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun Rev 7, 65-70 (2007)
82. C Monari, S Bevilacqua, M Piccioni, E Pericolini, S Perito, M Calvitti, F Bistoni, TR Kozel, A Vecchiarelli: A Microbial Polysaccharide reduces the Severity of Rheumatoid Arthritis by Influencing Th17 Differentiation and proinflammatory Cytokines production. J Immunol 183, 191-200 (2009)
83. A Mirshafiey, DT Ngoc Dzung, JW Murphy, MR Khorramizadeh, F Saadat, F Mehrabian, P Larsson: Tolerability and anti-inflammatory effects of glucuronoxylomannan in collagen-induced arthritis. Scand J Immunol 60, 226-232 (2004) (Pubitemid 39141252)
84. E Lubberts: IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?. Cytokine 41, 84-91 (2008)
85. P Miossec: Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum 48, 594-601 (2003) (Pubitemid 36301993)
86. M Ziolkowska, A Koc, G Luszczykiewicz, K Ksiezopolska-Pietrzak, E Klimczak, H Chwalinska-Sadowska, W Maslinski: High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 164, 2832-2838 (2000) (Pubitemid 30115519)
87. ML Cho, CH Yoon, SY Hwang, MK Park, SY Min, SH Lee, SH Park, HY Kim: Effector function of type II collagen-stimulated T cells from rheumatoid arthritis patients: cross-talk between T cells and synovial fibroblasts. Arthritis Rheum 50, 776-784 (2004)
88. K Sato, A Suematsu, K Okamoto, A Yamaguchi, Y Morishita, Y Kadono, S Tanaka, T Kodama, S Akira, Y Iwakura, DJ Cua, H Takayanagi: Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203, 2673-2682 (2006) (Pubitemid 44833343)
89. S Kotake, N Udagawa, N Takahashi, K Matsuzaki, K Itoh, S Ishiyama, S Saito, K Inoue, N Kamatani, MT Gillespie, TJ Martin, T Suda: IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103, 1345-1352 (1999) (Pubitemid 29218305)
90. PR Mangan, LE Harrington, DB O'Quinn, WS Helms, DC Bullard, CO Elson, RD Hatton, SM Wahl, TR Schoeb, CT Weaver: Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441, 231-234 (2006)
91. E Bettelli, Y Carrier, W Gao, T Korn, TB Strom, M Oukka, HL Weiner, VK Kuchroo: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238 (2006)
92. C Dong: TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 8, 337-348 (2008) (Pubitemid 351595217)
93. II Ivanov, BS McKenzie, L Zhou, CE Tadokoro, A Lepelley, JJ Lafaille, DJ Cua, D R Littman: The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126, 1121-1133 (2006) (Pubitemid 44380299)
94. TJ Harris, JF Grosso, HR Yen, H Xin, M Kortylewski, E Albesiano, EL Hipkiss, D Getnet, MV Goldberg, CH Maris, F Housseau, H Yu, DM Pardol, CG Drake: Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 179, 4313-4317 (2007)
95. AN Mathur, HC Chang, DG Zisoulis, GL Stritesky, Q Yu, JT O'Malley, R Kapur, DE Levy, GS Kansas, MH Kaplan: Stat3 and Stat4 direct development of IL-17-secreting Th cells. J Immunol 178, 4901-4907 (2007) (Pubitemid 46595272)
96. D Matusevicius, P Kivisakk, B He, N Kostulas, V Ozenci, S Fredrikson, H Link: Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 5, 101-104 (1999) (Pubitemid 29186827)
97. C Lock, G Hermans, R Pedotti, A Brendolan, E Schadt, H Garren, A Langer-Gould, S Strober, B Cannella, J Allard, P Klonowski, A Austin, N Lad, N Kaminski, SJ Galli, JR Oksenberg, CS Raine, R Heller, L Steinman: Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8, 500-508 (2002) (Pubitemid 34546753)
98. MB Teunissen, CW Koomen, R de Waal Malefyt, EA Wierenga, JD Bos: Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 111, 645-649 (1998) (Pubitemid 28452327)
99. T Aarvak, M Chabaud, P, Miossec, JB Natvig: IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 162, 1246-1251 (1999) (Pubitemid 29306992)
100. DJ Cua, J Sherlock, Y Chen, CA Murphy, B Joyce, B Seymour, L Lucian, W To, S Kwan, T Churakova, S Zurawski, M Wiekowski, SA Lira, D Gorman, RA Kastelein, JD Sedgwick: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744-748 (2003) (Pubitemid 36227625)
101. CA Murphy, CL Langrish, Y Chen, W Blumenschein, T McClanahan, RA Kastelein, JD Sedgwick, DJ Cua: Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 198, 1951-1957 (2003) (Pubitemid 38032126)